Micropatterned surfaces enable selective cancer cell capture and real-time monitoring. Manuscript 17 January 2018 Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Surfaces that facilitate selective cell adhesion using specific targeting moieties have significant implications in diagnostics, tissue engineering, and high-throughput screening. However, designing robust and spatially confined micropatterns for selective cell isolation on portable platforms remains highly challenging. Here, wettable silane (Si) micropatterns with covalently attached transferrin (Tf) for targeting Tf-overexpressing cancer cells are reported. These micropatterns are separated by carbon soot–based superhydrophobic regions, which transform the targeting sites into surface tension–confined “microwells.” These microwells facilitate the capture of human colorectal carcinoma cells (HCT116) and human cervical adenocarcinoma cells (HeLa) by confining their attachment to the wettable regions, thereby making the isolation and spotting of targeted cells more efficient. In addition, owing to its transparent nature, the Tf-conjugated wettability-based patterned chip enables real-time optical monitoring of cell adhesion, cell growth, and cell behavior. The specific cell isolation enabled by such surfaces has potential applications in developing cancer recurrence monitoring tests. Advanced Material Interfaces View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

OncoDiscover enables early cancer spread detection and faster diagnosis. | ET Health Press Release 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… A team of Pune scientists have discovered a technology that can detect within mere hours, the spread of cancer and claim that the new finding reduces considerably the time taken for detecting the disease. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process. Presently, in India, the final diagnosis report to detect the spread of cancer takes about 12 days whereas, with OncoDiscover technology, doctors can detect it in a mere 3.5 hours. Dr Khandare told ANI, "We felt the need for this technology because global cancer is spreading. 90 per cent of the people get to know they have cancer when it is at the second stage but through this technology, we can try saving that 90 per cent. This technology is needed to detect cancer at an early stage." View full article Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTC monitoring detects early HNSCC in chronic tobacco users in Bangladesh. Publications 8 June 2021 ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Background Tobacco consumption accounts for 1.6 million deaths annually in the South East Asia Region (SEAR). Notably, amongst the 10-20% of the global population consuming betel quid and tobacco, about an 81% concentration is in SEAR regions, including India and Bangladesh. The prevalence of HNSCC in these regions is rising alarmingly. For example, HNCs account for 23% of the total 156,775 cancer incidences in Bangladesh. Liquid biopsy tools are unavailable and expensive for most patients in this region. However, early cancer detection using tumor biomarkers, for example, circulating tumor cells (CTCs), is highly implicated. Furthermore, such biomarkers are being validated and have the potential for screening high-risk patients, such as those with a genetic predisposition or tobacco consumption. We report the first observational study in HNSCC patients in Bangladesh correlating the presence of CTCs to chronic tobacco consumption. Methods The study involved 70 cancer patients and 10 healthy volunteers (no prior cancer history). 87% of the patients had a specified history of chronic tobacco consumption. CTCs were isolated in 1.5 ml of blood using the OncoDiscover Liquid Biopsy Test, which is clinically approved by the Drug Controller General of India, and contains an enriching anti-EPCAM antibody immunomagnetic kit. CTCs are qualified as CK18+, DAPI+, and CD45-. Subsequently, CTCs were imaged using a Zeiss Axio Observer 7 and quantified for Mean Fluorescence Intensity (MFI) for clinicopathological parameters: age/gender, HNSCC sub-population, and CTC distribution. Results This is the 1st study on the Bangladesh phenotype accounting for the presence of CTCs in HNSCC patients. In this population, 34 males (66%) and 10 females (52%) accounted for 91 CTCs. CTC distribution was 0 to 6 with a mean and median of ~ 2.02 and 2, respectively. 25 patients (17 males, 8 females) were negative for any CTCs. Interestingly, 2 patients exhibited CTC clusters indicative of aggressive metastasis, in which 1 patient had no prior tobacco usage or family cancer history. There was no correlation between CTC presence in males (66%) and females (52%). Healthy volunteer samples exhibited no false positives. The MFI values ranged between 23 and 766, with mean and median MFI values of 157 and 96, respectively, indicative of CK overexpression on CTCs of HNSCC patients. Conclusions HNSCC patients with a history of chronic tobacco consumption in Bangladesh correlated with the presence of CTCs in 64% of the cases. Prospectively, CTCs may be validated as a biomarker for screening chronic tobacco users in Bangladesh to detect early cancers and HNSCC. Clinical Trial Information BMRC/Grants/2018/99 (1-100). Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTC and PD-L1 profiling across cancers supports monitoring, recurrence detection, and MRD. Publications 3 June 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Background India presents a diverse genetic pool with varying cancer incidence patterns. Common cancers in the Indian population include head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers. Understanding the distribution of circulating tumor cells (CTCs) across these cancers may help account for cellular minimal residual disease (MRD) and early recurrence in solid tumors. Surgery with curative intent can be further evaluated for residual disease using dual biomarkers such as ctDNA and CTCs. Methods In this retrospective analysis, peripheral blood samples from 5,935 patients across various cancer types—including head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers—were evaluated for the presence of CTCs, with and without PD-L1 overexpression and CTC clusters. CTCs were detected using the OncoDiscover platform approved by CDSCO in 1.5 mL of peripheral blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were confirmed as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was analyzed using linear fluorescence intensity gradients acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots to assess predictability across cancer types, age groups, stages, and genders. Results The study included 5,935 patient blood samples, comprising 90.07% baseline and 9.92% follow-up samples. CTC counts ranged from 1 to 10 per 1.5 mL of blood, with a mean value of 1.12. Among the patients, 69.87% (n = 2,854) demonstrated PD-L1 expression on their CTCs, with a mean value of 0.99. The 51–60-year age group exhibited the highest proportion of both total CTCs (19.16%, n = 1,137) and PD-L1–positive CTCs (19.71%, n = 805). Most CTC clusters were identified in breast, colorectal, and endometrial cancers. Pancreatic cancer patients showed the highest mean CTC count (1.4), whereas laryngeal cancer samples had the lowest mean count (0.78). The computational model indicated that the 51–60-year age group had the highest impact on cancer prevalence and mean CTC distribution. The model also demonstrated a strong correlation between blood-based outcomes and normal probability scores. Conclusions Higher CTC counts were strongly associated with advanced disease stages, particularly in cancers prone to hematogenous spread, such as breast, lung, and prostate cancers. Incorporating CTC profiling from baseline into diagnostic and surveillance strategies may enhance personalized cancer management. The presence of CTCs in disease-free survival (DFS) settings suggests potential links to poor therapeutic response, disease progression, and minimal residual disease. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Preoperative CTC levels predict prognosis and survival in oral squamous cell carcinoma. Manuscript 1 July 2022 Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Objective: The aim of this study was to investigate the presence of circulating tumor cells (CTCs) and their correlation with prognostic factors and clinical outcomes in treatment-naive patients with oral squamous cell carcinoma. Study design: CTCs were isolated using the OncoDiscover technique from presurgically obtained peripheral blood of 152 patients with treatment-naive oral squamous cell carcinoma. Sensitivity analysis was performed by including 40 healthy controls. CTC cutoff values for clinicopathologic factors were obtained from receiver operating characteristic curves. Multivariate models determined the significance of CTCs as independent variables. Kaplan–Meier analysis differentiated overall survival based on CTC values corresponding to disease stage. Results: Sensitivity, specificity, and accuracy of CTC detection were 94.32%, 98%, and 95.17%, respectively. The platform differentiated true positives at >3.5 CTCs (P < .00001). CTC counts above 20.5 were suggestive of nodal metastasis (P < .0001), with a linear trend for detecting occult metastasis (P = .061). Early and advanced stages could be differentiated by >13.5 CTCs (P < .0001). Elevated CTC levels were significantly associated with extranodal extension (>21.45 CTCs, P = .025), perineural invasion (>19.35 CTCs, P = .049), and depth of invasion (>12.5 CTCs, P = .0038). Median survival was reduced by 19 months when CTC levels were >13. Conclusions: Preoperative CTC levels demonstrated a strong correlation with adverse clinicopathologic factors and suggested their role as a sensitive prognostic marker for predicting survival outcomes and disease progression. (Oral Surg Oral Med Oral Pathol Oral Radiol 2022;134:73–83) View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

PD-L1 CTCs and clusters in gastric cancer support MRD detection and recurrence monitoring. Publications 3 November 2025 Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Authors Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Affiliations: Actorius Innovations and Research, Pune, Maharashtra, India Apollo Cancer Institute, Hyderabad, Telangana, India Apollo Cancer Centre, Chennai, Tamil Nadu, India Aster CMI Hospital, Bengaluru, Karnataka, India Renova Soumya Cancer Center, Hyderabad, Telangana, India Introduction Gastric cancer is associated with a high mortality rate, primarily due to late-stage diagnosis, which reduces the effectiveness of treatments such as surgery and results in poor five-year survival outcomes. The rate of metastasis in early-stage gastric cancer (EGC) varies, with reported lymph node metastasis rates ranging from approximately 10% to over 23%, depending on factors such as tumor invasion depth. Although most EGC cases do not initially present with distant metastasis, a substantial proportion of patients are diagnosed at advanced, metastatic stages. In this study, we evaluated gastrointestinal cancer patients for minimal cellular residual disease using circulating tumor cells (CTCs) expressing PD-L1 and the presence of CTC clusters. Methods A total of 58 gastric cancer samples were retrospectively analyzed. CTCs were isolated using the CDSCO India–approved OncoDiscover® CTC Test, which employs immunomagnetic enrichment with anti-EpCAM antibodies. CTCs were identified through immunocytochemical staining as CK18⁺, DAPI⁺, and CD45⁻ cells. Fluorescence imaging was performed using a Zeiss Axio Observer 7 microscope, and signal intensities were quantified. PD-L1 expression on CTCs was also evaluated. Statistical analyses summarized total CTC counts, PD-L1–positive CTCs, and the presence of CTC clusters. Results Among the 58 gastric cancer patient samples analyzed, CTCs were detected in 62.1% (36/58) of cases, while 37.9% (22/58) were CTC-negative. Most samples (93.1%) were collected at baseline, and 6.9% at follow-up. Among CTC-positive cases, PD-L1 expression was observed in 51.7%, while 8.7% were PD-L1-negative. CTC clusters were identified in 83.3% (30/36) of CTC-positive patients. Regarding CTC count distribution, 31.0% of patients had one CTC, 18.9% had two, and 12.07% had three CTCs. For PD-L1–positive CTCs, 14.3% of patients had zero detectable CTCs, 51.4% had one, 25.7% had two, and 8.6% had three CTCs. The mean CTC count across all samples was 1.0, the mean number of PD-L1–positive CTCs was 0.8, and the mean cluster count was 0.1. Demographic analysis showed male predominance (61.1%), with the most represented age group being 61–70 years (29.6%), followed by 41–50 years (22.2%) and 51–60 years (20.4%). Conclusions CTCs, particularly those expressing PD-L1 and forming clusters, are prevalent in gastric cancer patients and may serve as valuable biomarkers for diagnosis and prognosis. Their detection may help assess minimal cellular residual disease (MCRD) and identify patients at risk of recurrence. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Manuscript 15 July 2024 Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Engineering inverse 3D polymeric microfilms with controlled spatial hierarchy is both highly challenging and critically important at the intersection of biology and materials science. These structures hold significant potential for enhancing selective cell–surface interactions, including cell adhesion and growth. Protein-modified inverse 3D polymeric microfilms can further promote selective cell capture and adhesion. In this study, we report the fabrication of inverse 3D polymeric microfilms using composite polymeric–bioligand conjugated films designed to enhance the capture of circulating tumor cells (CTCs) from the blood of cancer patients. The microfilms were developed using functionalized poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA), mediated with the ligand transferrin. Protein immobilization on the films was achieved by conjugating transferrin (Tf), collagen (Co), and bovine serum albumin (BSA) to promote cellular adhesion and capture. The films were characterized using scanning electron microscopy (SEM), attenuated total reflectance infrared spectroscopy (ATR-IR), and contact angle measurements, revealing micropores ranging from 18–26 μm. Confocal laser scanning microscopy (CLSM) demonstrated enhanced cell attachment on the polymeric-blend microfilms, confirming improved cell adhesion, capture, and the ability of cells to proliferate within the 3D structure. The inverse 3D polymeric microfilms achieved an 80% cell capture efficiency with cultured cancer cells. In clinical utility, their CTC capturing efficiency was comparable to OncoDiscover® CTC enumeration technology. These inverse 3D polymeric microfilms represent a novel ‘lab-on-a-chip’ platform capable of enabling CTC enumeration for monitoring minimal residual disease (MRD), tracking metastatic progression, evaluating treatment response, and enabling early detection of relapse. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTC monitoring in breast cancer detects MRD and supports post-surgery surveillance. Publications 3 November 2025 Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Introduction Early detection of metastasis is important for improving overall survival in breast cancer (BC) patients. Circulating tumor cells (CTCs) play a role in detecting minimal residual disease (MRD). In an ongoing cohort, we evaluated the association between CTC dynamics before and after surgery performed with curative intent. Additionally, we assessed cancer-related worry in post-surgical BC patients. Methods A total of 75 CTC tests were performed on 55 female BC patients, of whom 20 were follow-up cases. In an ongoing IEC-approved clinical cohort, 10 BC patients were enrolled using a quantitative, non-probability purposive sampling method. CTC counts, including clusters, were measured both pre-surgery and 24 hours post-surgery. PD-L1 expression on CTCs was assessed using the CDSCO-approved OncoDiscover platform. Patient-reported outcome measures (PROMs) were evaluated using the Breast-Q Cancer Worry scale, a validated subscale reflecting fear of recurrence and related concerns. Statistical analysis compared PROM scores with CTC patterns, including increase, persistence, or clearance. A paired sample t-test was applied to compare pre- and post-operative PROM scores to evaluate changes in cancer-related worry in relation to CTC counts. Results Among the 75 tests performed in 55 BC patients, 84.5% were CTC-positive, with a mean of 1.43 CTCs per test. In longitudinal monitoring of 10 female BC patients who underwent surgery, six received neoadjuvant chemotherapy (NACT) followed by breast-conserving surgery, while four underwent surgery without prior chemotherapy. Overall, 40% (4/10) showed a reduction in CTC counts, and 20% (2/10) achieved complete CTC clearance after surgery. Patients with increased post-surgery CTC counts reported a significant increase in cancer-related worry. The mean pre-surgery score was 43.9, which increased to 51.8 after surgery. These findings suggest the need for targeted emotional and psychological support in the post-surgical period and highlight the role of CTC monitoring in assessing MRD. Conclusions Monitoring CTCs strengthens their potential as an early indicator of residual disease by providing important clinical insights into tumor activity during the operative phase. Further validation is warranted to support more integrated, patient-centered care approaches aimed at reducing the burden of advanced cancer. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Read real-world case studies demonstrating how circulating tumor cell analysis can support cancer monitoring, treatment decisions, and clinical insights. Case Studies Innovation in Action Real-world cases studies, outcomes, and success stories demonstrating how our technology is transforming cancer patient care. Below are some of the patient case-studies: Case Study 01 Patient Details Female 74 yrs Clinical Presentation Ca Breast pT2pNO HR+/ HER2– Clinical History Patient underwent surgery. We advised ONCOTYPE Dx but patient was unaffording. We needed to decided between adjuvant chemotherapy and hormonal therapy. Test Result 4 CTCs were found with 1 CTC Cluster indicating highly aggressive disease. Clinical Outcome Given her age – it was difficult to tolerate chemo. 4# TC – hormonal therapy X 7.5 yrs Case Study 02 Patient Details Male 45 yrs Clinical Presentation CA rectum Clinical History NACT+RT – Sx- CT (delayed due to myelosuppression). PET Scan and CTC test done at end of therapy. Test Result 4 CTCs were found with 1 CTC Cluster indicating highly aggressive disease. PET Scan confirmed multiple liver mets. Clinical Outcome Patient underwent surgery. Patient was unaffording for chemo and expired shortly. Case Study 03 Patient Details Female 60 years Clinical Presentation CA Breast ER-/PR-/HER2 3+ Clinical History Sx-L.MRM-pT2N0 CHEMO-6 #TCH +2 # Herceptin (no funds)- on f/u. PET Scan and CTC test suggested. Test Result 2 CTCs were found indicating residual disease. PET Scan confirmed liver mets. Clinical Outcome Meta analysis by TMH suggests that 6 months Herceptin is equal to 12 months. In this particular case, 6M of Herceptin was not enough as patient developed liver mets. Case Study 04 Patient Details Female 60 years Clinical Presentation CA Breast Suspicious lung nodules on PET SCAN Clinical History Sx –RT.MRM- pT2N2MO CHEMO- ACX 4- TH X4 – Herceptin x 17 doses CTC test was done post surgery and post chemotherapy. Test Result 2 CTCs were found Surgery. 0 CTCs were found post chemotherapy. Clinical Outcome After 17 cycles of Herceptin, since CTC and PET was normal, hence we stopped at 1 yr of therapy. Case Study 05 Patient Details Female 64 years Clinical Presentation Ca Ovary Stage IIIC Clinical History NACT x 3 #pacli –Carbo - ICS – Adj chemo X 3 # Pacli – Carbo-On f/u CTC test was suggested post treatment. Test Result 1 CTC were found in CTC Cluster form indicating aggressive residual disease. CA125 was within normal limits. CT scan – local recurrence Clinical Outcome Patient was put on Oral Metronomic Chemotherapy (OMCT) Case Study 06 Patient Details Female 33 years Clinical Presentation Ca Ovary Stage IIIC Clinical History Primary cytoreduction done 4 yrs back. 6 #CT – PACLI-CARBO, counselled but PARPi not available hence didn't go for germline testing. Patient was monitored with CTC test. Test Result 2 CTCs were found during monitoring which indicated recurrence • PET CT showed recurrence. Clinical Outcome Recurrence in liver, hence surgery repeated. Lipodox –Carbo x 6 #. Patient was found to be BRCA+. Patient was put on Rucaparib (8 months). CTC is 0 on follow up. Case Study 07 Patient Details Male 33 years Clinical Presentation Sigmoid colon with peritoneal metastasis Clinical History FOLFOX x 4 # - very good partial response. SX--HIPEC FOLFOX X8 # +Bevacizumab maintenance Patient was monitored with CTC test. Test Result 1 CTC was found in CTC Cluster form indicating aggressive residual disease. Recurrence in liver found by PET Scan. Clinical Outcome Patient succumbed to disease. Case Study 08 Patient Details Female 45 years Clinical Presentation Ca Breast TNBC Clinical History RT.MRM -pT= 4.5 cm,N0. BRCA +ve 4# AC-T x 4#-XRT to CW/SCF. 1 yr of capecitabine (low dose) Patient was monitored with CTC test. Test Result Longitudinal monitoring by CTC test shows absence of CTCs. Clinical Outcome Patient on clinical follow up Case Study 09 Patient Details Female 68 years Clinical Presentation Ca Breastp T2N2M0 ,ER+/PR+/HER2+(fish negative) Clinical History Acx 4- Taxanes x 12 –XRT to CW/SCF. Patient monitored with CTC test. Test Result After initial treatment, 2 CTCs with 1 CTC Cluster was found. Clinical Outcome Treatment was changed to capecitabine + hormonal therapy. Longitudinal monitoring by CTC test shows absence of CTCs. Case Study 10 Patient Details Male 55 years Clinical Presentation Ca Colon with solitary liver mets. Clinical History NACT- folfirinox x 4# SX for colon and liver Adj . FOLFOX X 8#. Patient monitored with CTC test. Test Result Latest CTC test shows, 2 CTCs. However, both PET and MRI are negative. There is discordance between CTC and imaging techniques. Clinical Outcome Patient on follow up. CTC may be repeated in 3 months. Case Study 11 Patient Details Female 50 years Clinical Presentation Ca Ovary Stage IIIC Clinical History Primary cytoreduction 6# pacli- carbo Test Result 2 CTCs were found indicating residual disease. PET Scan confirmed local recurrence. Clinical Outcome Patient was put on Oral Metronomic Chemotherapy (OMCT) Case Study 12 Patient Details Female 50 years Clinical Presentation Ca Breast – RT MRM done p/w sternal mets and ipsilateral SC LN mets Clinical History No chemo/RT/HT taken due to fear Chemo- AC x 6# - XRT to sternal including Supraclav field Hormonal therapy x 10 yrs Test Result 0 CTC were found. PET Scan confirmed normal Clinical Outcome Patient on normal follow up. Case Study 13 Patient Details Male 55 years Clinical Presentation Ca Breast TNBC Clinical History MRM- XRT to CW /SCF NACT – 4 #AC – Pacli- carbo X 12 # Capecitabine x 1year Test Result From 2 CTCs (1 Cluster) during baseline, CTC first monitoring showed progress with 0 CTCs . However, latest CTC test shows 1 CTC. However, both PET and MRI are negative. Clinical Outcome Early signs of possible drug resistance . Patient on follow up. Case Study 14 Patient Details Female 19 years Clinical Presentation Ca Colon Clinical History Stage pT4N2 Capox x 8# Test Result 4 CTCs were found indicating aggressive residual disease. Recurrence in liver found by PET Scan. Clinical Outcome Patient succumbed to disease. First Prev 1 Page 1 Next Last Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Antibody-coated cotton substrate for CTC enumeration and chemotherapy response. Manuscript 18 February 2022 Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Circulating tumor cells (CTCs) are distinct cancer biomarkers established in clinical settings for early cancer detection, metastasis progression, and minimal residual disease (MRD) monitoring. Despite numerous advances, comprehensive molecular characterization of CTCs remains extremely challenging due to their rarity and heterogeneity. Here, we present a novel cotton microfluidic substrate (CMS) as an innovative biomedical matrix that efficiently isolates CTCs while facilitating in vitro CTC expansion, enabling further downstream analysis of these rare cells. CMS enabled both static and dynamic isolation of cells from the MCF-7 cancer cell line, as well as from the blood of head and neck squamous cell carcinoma (HNSCC) patients. The cell capture efficiencies were further compared with the clinically regulated OncoDiscover® Liquid Biopsy Test. Furthermore, CMS served as a matrix on which the captured cancer cells were grown into 3D tumor models to study anti-cancer drug efficacy and multi-drug resistance (MDR) mechanisms. The design of the CMS employed two different surface chemistries—flattened and nanostructured surfaces—each conjugated with anti-EpCAM antibodies to evaluate CTC capture efficiency and 3D tumor growth dynamics. The nanostructured surface was highly efficient in capturing CTCs and promoted 3D tumor spheroid formation, showing a five-fold increase in size from day 3 to day 10 of culture. Moreover, when treated with the anti-cancer drug cisplatin, an almost half reduction in tumor size was achieved within 24 hours, followed by a cytostatic threshold and the eventual acquisition of drug resistance within three days. Conclusively, the CMS matrix exhibits potential for the further development of “tissue-on-chip” and “point-of-care” medical devices in cancer diagnostics, as well as for evaluating chemotherapeutic efficacy in drug discovery and development. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations | Dainik Jagran Press Release 14 March 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Click the button below to read the full story Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

HER2 analysis on CTCs enables real-time monitoring in metastatic breast cancer. Publications 10 April 2024 AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Introduction: Breast cancer accounts for 12.5% of all new annual cancer cases worldwide. Cases classified as HER2-positive tend to proliferate, metastasize, and often lead to relapse. HER2 is one of the most valid tumor markers and is widely used as a diagnostic and prognostic biomarker in metastatic breast cancer (MBC). Thus, analyzing the expression of HER2 on circulating tumor cells (CTCs) can offer a real-time dynamic biomarker for guiding treatment options between endocrine therapy and chemotherapy in advanced breast cancer. Functional assays on CTCs with the HER2 biomarker offer evolving diagnostic opportunities, especially when tissue samples are not accessible or are inadequate. Methods: Retrospectively, blood samples from 179 breast cancer patients were analyzed for the presence of CTCs using the OncoDiscover® platform approved by the Drug Controller General of India (CDSCO). The platform consists of an immunomagnetic multi-component system mediated by anti-EpCAM antibodies. The isolated cells were immunostained using the nuclear dye DAPI along with CK18, CD45, and HER2 antibodies. CTCs were identified by the presence of HER2-positive, CK18-positive, DAPI-positive, and CD45-negative staining. Validation of HER2 expression on CTCs was analyzed based on the linear intensity gradients of fluorescence signals. CTCs were termed HER2-negative when weak or no detectable fluorescence signal was observed and HER2-positive when high fluorescence signals were detected. Results: Among the cohort of 179 patient samples, 63.68% of samples showed the presence of CTCs, with counts ranging from 1–7 CTCs. Among these, 47.84% of the detected CTCs showed HER2 expression. The mean fluorescence intensity value for HER2 expression in CTCs was found to be 3.23. The observed fluorescence intensity further emphasizes the robustness of CTCs as a viable source for molecular characterization. Conclusion: Integration of HER2 analysis on CTCs into the clinical assessment of metastatic breast cancer may offer a non-invasive, real-time strategy for tumor profiling and may help pave the way for more precise and tailored therapeutic interventions. Know more Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test